Prevention of COVID-19 variant (omicron JN.1)

Clinical trials for Prevention of COVID-19 variant (omicron JN.1) explained in plain language.

Never miss a new study

Get alerted when new Prevention of COVID-19 variant (omicron JN.1) trials appear

Sign up with your email to follow new studies for Prevention of COVID-19 variant (omicron JN.1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Can a Self-Amplifying RNA vaccine outsmart the latest COVID variant?

Vaccine Not yet recruiting

This early-stage trial tests a new vaccine called BMI2012, designed to protect against the Omicron JN.1 variant of COVID-19. Healthy adults aged 19 to 55 receive a single injection of either the vaccine or a placebo. Researchers will check how safe the vaccine is and whether it t…

Matched conditions: PREVENTION OF COVID-19 VARIANT (OMICRON JN.1)

Phase 1 • Sponsor: BMI Korea • Aim: Vaccine

Last updated Aug 30, 2026 00:00 UTC

Prevention of COVID-19 variant (omicron JN.1)

Get alerted when new Prevention of COVID-19 variant (omicron JN.1) trials appear

Can a Self-Amplifying RNA vaccine outsmart the latest COVID variant?